Abstract Title:

Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro.

Abstract Source:

Am J Surg. 2010 Nov;200(5):577-80. PMID: 21056131

Abstract Author(s):

Patrick Mannal, Debbie McDonald, David McFadden

Article Affiliation:

The University of Vermont/Fletcher Allen Health Care, Burlington, USA. [email protected]

Abstract:

BACKGROUND: Tamoxifen is widely used for the treatment of breast cancer. Pterostilbene, a bioavailable stilbenoid found in blueberries, has been found to inhibit breast cancer growth in vitro. It was hypothesized that combining pterostilbene with tamoxifen would produce additive effects on estrogen receptor-positive breast cancer cells.

METHODS: Two estrogen receptor-positive breast cancer cell lines, MCF7 and ZR-751, were pretreated with graduated doses of pterostilbene for 24 hours, followed by 5μmol/L tamoxifen. MTT proliferation assays and Cell Death Detection ELISA(PLUS) tests evaluated cell viability and apoptosis.

RESULTS: MCF7 cells showed inhibition (10 and 20μmol/L, P<.001; 30μmol/L, P<.05) at all time points when combined with tamoxifen. ZR-751 cells showed additive reductions in cell viability (P<.001). Cell Death Detection ELISA(PLUS) indicated increased apoptosis (P<.01).

CONCLUSIONS: Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.